### Abbreviations

- ATV atazanavir
- DRV darunavir
- LPV lopinavir
- EFV efavirenz
- ETV etravirine
- NVP nevirapine
- RPV rilpivirine
- MVC maraviroc
- DTG dolutegravir
- RAL raltegravir
- ABC abacavir
- FTC emtricitabine
- 3TC lamivudine
- TDF tenofovir disoproxil fumarate
- ZDV zidovudine
- E/C/F/ Elvitegravir/Cobicistat/FTC
- TAF tenofovir alafenamide

### Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No a priori dosage adjustment is recommended.

### Text Legend

- ↑ Potential increased exposure of the hormone
- ↓ Potential decreased exposure of the hormone
- ↔ No significant effect

- a Monitor for signs of estrogen deficiency.
- b The clinical significance of increased progestin exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown.

### HRT Treatment Selector

<table>
<thead>
<tr>
<th>Drug</th>
<th>ATV/r</th>
<th>DRV/r</th>
<th>LPV/r</th>
<th>EFV</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>MVC</th>
<th>DTG</th>
<th>RAL</th>
<th>ABC</th>
<th>FTC</th>
<th>3TC</th>
<th>TDF</th>
<th>ZDV</th>
<th>E/C/F</th>
<th>E/C/F/TAF</th>
<th>E/C/F/TDF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drosiprenone</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dydrogesterone</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone (oral)</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norethisterone (Norethindrone)</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norgestrel</td>
<td>↑b</td>
<td>↑b</td>
<td>↑b</td>
<td>↓a</td>
<td>↓a</td>
<td>↓a</td>
<td>↔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.